Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. Boosts Holdings in Axsome Therapeutics, Inc. $AXSM

Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. boosted its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 14.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 326,318 shares of the company’s stock after purchasing an additional 40,824 shares during the quarter. Axsome Therapeutics comprises about 4.0% of Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings, making the stock its 12th biggest holding. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A.’s holdings in Axsome Therapeutics were worth $34,064,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Principal Financial Group Inc. lifted its stake in shares of Axsome Therapeutics by 42.8% in the first quarter. Principal Financial Group Inc. now owns 295,671 shares of the company’s stock worth $34,484,000 after buying an additional 88,606 shares in the last quarter. Penserra Capital Management LLC bought a new position in Axsome Therapeutics in the 1st quarter valued at approximately $2,229,000. Trek Financial LLC purchased a new stake in Axsome Therapeutics during the 1st quarter valued at $3,446,000. Edgestream Partners L.P. purchased a new stake in Axsome Therapeutics during the 1st quarter valued at $8,174,000. Finally, Nuveen LLC bought a new stake in shares of Axsome Therapeutics in the 1st quarter worth $48,185,000. 81.49% of the stock is owned by hedge funds and other institutional investors.

Axsome Therapeutics Stock Performance

AXSM opened at $121.71 on Friday. The company’s 50 day moving average is $116.84 and its 200 day moving average is $109.93. The company has a current ratio of 1.57, a quick ratio of 1.51 and a debt-to-equity ratio of 1.66. The company has a market cap of $6.07 billion, a price-to-earnings ratio of -24.01 and a beta of 0.52. Axsome Therapeutics, Inc. has a 12-month low of $75.56 and a 12-month high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last announced its earnings results on Monday, August 4th. The company reported ($0.92) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.08. The business had revenue of $150.04 million during the quarter, compared to analysts’ expectations of $140.02 million. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. On average, equities research analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Buying and Selling

In related news, COO Mark L. Jacobson sold 45,783 shares of Axsome Therapeutics stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $114.48, for a total transaction of $5,241,237.84. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Roger Jeffs sold 20,000 shares of the company’s stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $121.60, for a total value of $2,432,000.00. Following the completion of the sale, the director owned 90,974 shares of the company’s stock, valued at approximately $11,062,438.40. The trade was a 18.02% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 243,332 shares of company stock valued at $28,824,746. 22.30% of the stock is owned by company insiders.

Analyst Ratings Changes

AXSM has been the topic of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a report on Wednesday. Needham & Company LLC restated a “buy” rating and set a $150.00 target price on shares of Axsome Therapeutics in a research note on Monday, August 4th. Bank of America lifted their price target on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the stock a “buy” rating in a research note on Tuesday, August 5th. Wells Fargo & Company raised shares of Axsome Therapeutics to a “strong-buy” rating in a report on Wednesday, September 3rd. Finally, Royal Bank Of Canada raised their target price on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the stock an “outperform” rating in a report on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $177.93.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.